Volume 14, Number 4—April 2008
Clostridium difficile Surveillance Trends, Saxony, Germany
Highlight and copy the desired format.
|EID||Burckhardt F, Friedrich A, Beier D, Eckmanns T. Clostridium difficile Surveillance Trends, Saxony, Germany. Emerg Infect Dis. 2008;14(4):691-692. https://dx.doi.org/10.3201/eid1404.071023|
|AMA||Burckhardt F, Friedrich A, Beier D, et al. Clostridium difficile Surveillance Trends, Saxony, Germany. Emerging Infectious Diseases. 2008;14(4):691-692. doi:10.3201/eid1404.071023.|
|APA||Burckhardt, F., Friedrich, A., Beier, D., & Eckmanns, T. (2008). Clostridium difficile Surveillance Trends, Saxony, Germany. Emerging Infectious Diseases, 14(4), 691-692. https://dx.doi.org/10.3201/eid1404.071023.|
To the Editor: Vonberg et al. (1) recently commented on the increase of Clostridium difficile seen in US hospitals by using discharge diagnoses and confirmed the observation from the United States (2) with hospital discharge data from Germany during 2000 through 2004. C. difficile ribotype 027 has recently been isolated in Germany (3). We further contribute to the assessment of C. difficile as an emerging threat by looking at population surveillance data.
C. difficile is not a federal notifiable disease in Germany, which limits our ability to analyze national surveillance trends. However, in 2002 the state of Saxony implemented additional mandatory surveillance of community- and hospital-acquired infectious enteritis caused by laboratory-confirmed C. difficile.
To check for an increase in notifications due to reporting bias of gastroenteric diseases, we compared the quarterly incidence data from 2002 through 2006 with data on Salmonella spp. infections (usually reported by local general practitioners) and rotavirus and norovirus infections (both usually reported by clinics). The potential problem of reporting bias for gastroenteric diseases has been addressed recently (4). Information about age and sex of C. difficile patients was available for 2006 only.
Quarterly incidences for C. difficile in Saxony were from 1.7–3.8 per 100,000 population in 2002 and 2003 and continued to increase to 14.8 cases per 100,000 population in 2006 (Figure). This constitutes a 6-fold increase of the yearly average of C. difficile incidence rates between 2002 and 2006. The third quarter of 2005 experienced a sharp drop that could not be explained retrospectively and might have resulted from transition to new procedures for data collection and management.
Gastroenteric infections showed clear seasonality with a slightly decreasing yearly trend for Salmonella spp. and seasonal values from 13.8 cases per 100,000 in winter to summer peaks of 56.8. Rotavirus infections displayed an even stronger seasonality, with values from 7.0 cases per 100,000 in summer to winter peaks of 140.3. Norovirus infections peaked again during winter, at 137.2 cases per 100,000 but had as few as 11.0 cases per 100,000 during summer. Notification does not suggest reporting bias of gastroenteric infections.
Elderly persons, i.e., those >65 years of age, were affected most by C. difficile infections; this age group accounted for 1,506 (65%) of all cases (n = 2,306) in 2006. The 45- to 64-year age group had the next highest number of cases, 451 (20%). Men and women were affected equally in the different age groups; slightly more women (n = 805) than men (n = 701) with C. difficile infection were >65 years of age.
According to state and local health departments, there were no major health campaigns since 2004 that might have selectively increased awareness for C. difficile notification. Our results show a continuous increase of cases that even reaches seasonal notification levels of Salmonella spp. and Rotavirus infections, but the increase is difficult to explain entirely by changes in reporting behavior. We emphasize the role of individual German states in setting additional surveillance targets for public health. Given the epidemic potential and the severity of the disease, especially among the elderly, surveillance of C. difficile should be introduced throughout Germany along with enhanced prevention and treatment strategies (5).
- Vonberg RP, Schwab F, Gastmeier P. Clostridium difficile in discharged inpatients, Germany. Emerg Infect Dis. 2007;13:179–80.
- McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerg Infect Dis. 2006;12:409–15.
- Kleinkauf N, Weiss B, Jansen A, Eckmanns T, Bornhofen B, Küehnen E, Confirmed cases and report of clusters of severe infections due to Clostridium difficile PCR ribotype 027 in Germany. Euro Surveill. 2007 Nov 15;12(11):E071115.2.
- Wilcox M, Fawley W. Viral gastroenteritis increases the reports of Clostridium difficile infection. J Hosp Infect. 2007;66:395–6.
- McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol. 2007;28:140–5.
- Figure. Quarterly incidence per 100,000 population of Clostridium difficile infections compared with gastroenteric infections caused by Salmonella spp., rotaviruses, and noroviruses in Saxony, Germany, 2002–2006. Note the log scale on the...
Please use the form below to submit correspondence to the authors or contact them at the following address:
Florian Burckhardt, Robert Koch Institute, Infectious Diseases, Seestr 10, Berlin 13353, Germany;
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: July 13, 2010
- Page last updated: July 13, 2010
- Page last reviewed: July 13, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)